Leerink Partners Maintains Outperform on DexCom, Lowers Price Target to $87
Portfolio Pulse from Benzinga Newsdesk
Leerink Partners has maintained an 'Outperform' rating on DexCom but has lowered the price target from $90 to $87.
October 25, 2024 | 1:23 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Leerink Partners has maintained an 'Outperform' rating on DexCom but has lowered the price target from $90 to $87.
The 'Outperform' rating suggests continued confidence in DexCom's performance, but the lowered price target indicates some caution. This mixed signal may result in a neutral short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100